Result for
Tag: vaccines
May 25, 2021
Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants
Prevalence of anti-SARS-CoV-2 antibodies in a cohort of 367 solid organ transplant recipients in France who received an mRNA COVID-19 vaccine was 1.4% at baseline, 6.3% prior to the second dose, and 34% at 1 month after the second dose. The vaccines were well tolerated with only one serious adverse event reported. Marion et al. (May…
May 24, 2021
Single-Dose BNT162b2 MRNA COVID-19 Vaccine Significantly Boosts Neutralizing Antibody Response in Health Care Workers Recovering from Asymptomatic or Mild Natural SARS-CoV-2 Infection
Among healthcare workers (HCW) who had previously been infected with SARS-CoV-2 and had mild or no symptoms (n = 41), one dose of the Pfizer-BioNTech vaccine resulted in higher levels of neutralizing antibody titers than those found in HCW who had received two doses of the vaccine (n = 16) but had never been infected. …
Efficacy Estimates for Various COVID-19 Vaccines What We Know from the Literature and Reports
[Pre-print, not peer-reviewed] A report using data from publications, reports, and press releases concluded that the average efficacy of the Pfizer-BioNTech, Moderna, Johnson & Johnson/Janssen, Oxford-AstraZeneca, Sputnik, Novavax, Sinovac, and Sinopharm vaccines was about 85% against any disease with infection. Vaccine efficacy was >80% for all vaccines included except for Sinovac (51%, 95% CI 36-62%)….
May 20, 2021
Thrombocytopenia Including Immune Thrombocytopenia after Receipt of MRNA COVID-19 Vaccines Reported to the Vaccine Adverse Event Reporting System (VAERS)
An analysis of reported adverse events following vaccination with an mRNA COVID-19 vaccine indicates that the reported number of thrombocytopenia cases does not suggest a safety concern attributable to mRNA COVID-19 vaccines at this time. Fifteen cases of thrombocytopenia were identified among 18,841,309 doses of Pfizer-BioNTech vaccine and 13 cases among 16,260,102 doses of Moderna…
May 19, 2021
Neutralizing Antibody Levels Are Highly Predictive of Immune Protection from Symptomatic SARS-CoV-2 Infection
Vaccine efficacy of 7 COVID-19 vaccines correlated well with reported vaccine-elicited neutralization titers (r=0.9), according to an analysis of phase 3 vaccine trial data. Using data from the trials and neutralization data from cohorts of convalescent patients, the authors estimated that levels of vaccine-elicited anti-SARS-CoV-2 neutralizing antibodies required for 50% protection against detectable SARS-CoV-2 infection…
Effectiveness of BNT162b2 MRNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Mortality Following COVID-19
[Pre-print, not peer-reviewed] Even in the small percentage of vaccine recipients who develop symptomatic disease, vaccination with either the Pfizer-BionNTech vaccine or the Oxford-AztraZeneca vaccine conferred additional protection against death, according to analysis of data from England. Among adults aged ≥70 years with COVID-19, those vaccinated with 1 dose of the Pfizer-BioNTech vaccine, 1 dose…
May 18, 2021
Extended Interval BNT162b2 Vaccination Enhances Peak Antibody Generation in Older People
[Pre-print, not peer-reviewed] Adults aged >80 years with 11-12 week intervals between doses of the Pfizer-BioNTech vaccine (n=79) had 3.5-fold higher peak titers of anti-SARS-CoV-2 spike antibodies compared to adults >80 given a standard three-week interval between doses (n=68) in a cohort study of in the UK. However, the magnitude of spike-specific T cell responses…
The Effectiveness of the TWO-DOSE BNT162b2 Vaccine: Analysis of Real-World Data
The Pfizer-BioNTech vaccine was 90% effective in preventing any SARS-CoV-2 infection when comparing incidence of infection between 7-27 days after the second dose (protection period) vs 1-7 days after the first dose (reference period). The findings are based on a cohort belonging to a large health provider in Israel (n=1.2 million), of which 74% had…
May 13, 2021
Neutralization Potential of Covishield Vaccinated Individuals against B.1.617.1
[Pre-print, not peer-reviewed] Individuals with prior SARS-CoV-2 infection (n=18) had 24-fold higher levels of anti-SARS-CoV-2 neutralizing antibodies (nAbs) against the B.1.617.1 variant, which is linked to recent surges in cases in India, 4 weeks after the second dose of the Covishield vaccine (Oxford-AstraZeneca vaccine version manufactured in India), compared to those without a previous history…
Guidance for Fully Vaccinated People
The CDC released updated guidance as of May 13, 2021 that fully vaccinated individuals (2 weeks after a single dose vaccine or 2 weeks after the second dose of a 2-dose vaccine) no longer need to wear face coverings or physically distance in most indoor and outdoor settings regardless of crowd size. Officials at the…
Previous page Next page